ArticleNanomaterials (Basel, Switzerland)2026
Synthesis of Modified Silver- or Copper-Loaded Silica Nanocarriers as a Tool for Curcumin Delivery.
Article in Nanomaterials (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mesoporous silica nanoparticles (MSNs) constitute a promising platform for curcumin delivery, mitigating its pharmacokinetic limitations and enabling controlled release at the target site. The incorporation of metals may further enhance the therapeutic effects of curcumin. In this study, a series of curcumin carriers based on MSNs decorated with silver or copper and aminopropyl groups was produced. The resulting nanomaterials contained CuO and AgBr crystallites and exhibited uniform mesoporosity, large pore volumes, and specific surface areas. These materials were evaluated for curcumin delivery, cytotoxicity toward normal and cancer cells of intestinal origin, and antimicrobial activity against a wide range of bacteria and fungi. The most favorable properties were exhibited by the carrier containing AgBr and aminopropyl groups, which showed a selectivity index of 3.8 for cancer cells relative to healthy cells, the highest anticancer activity (IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.